ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
vTv Therapeutics Inc

vTv Therapeutics Inc (VTVT)

15.32
-0.31
( -1.98% )
업데이트: 03:40:05

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

주요 통계 및 세부정보

가격
15.32
매수가
15.30
매도가
15.43
거래량
8,199
15.2071 일간 변동폭 15.92
7.38 52주 범위 30.99
market_cap
전일 종가
15.63
개장가
15.74
최근 거래 시간
1
@
15.42
마지막 거래 시간
03:40:08
재정 규모
US$ 124,857
VWAP
15.2283
평균 볼륨(3m)
27,723
발행 주식
3,189,606
배당수익률
-
주가수익률
-2.46
주당순이익(EPS)
-6.35
매출
-
순이익
-20.25M

vTv Therapeutics Inc 정보

vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (... vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (TTP488), an orally administered drug. Its other products include TTP399, type II diabetes drug candidate. TTP399 is also an orally administered drug that targets the glucagon-like peptide-1 receptor. It also has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
본부
Wilmington, Delaware, USA
설립됨
-
vTv Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker VTVT. The last closing price for vTv Therapeutics was US$15.63. Over the last year, vTv Therapeutics shares have traded in a share price range of US$ 7.38 to US$ 30.99.

vTv Therapeutics currently has 3,189,606 shares in issue. The market capitalisation of vTv Therapeutics is US$49.85 million. vTv Therapeutics has a price to earnings ratio (PE ratio) of -2.46.

VTVT 최신 뉴스

기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.14-0.90556274256115.4616.314.861195315.581266CS
41.359.6635647816813.9718.3112.624482714.71696575CS
120.090.5909389363115.2318.3112.622772314.75177913CS
26-7.91-34.05079638423.2324.912.12012750716.21999052CS
523.3527.986633249811.9730.997.383513216.02073618CS
156-33.08-68.34710743848.4567.3818427829.91070754CS
260-45.08-74.635761589460.4205.27.3890010499.46992263CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
CTNTCheetah Net Supply Chain Service Inc
US$ 5.53
(195.72%)
107.05M
ZJKZJK Industrial Company Ltd
US$ 15.01
(136.75%)
20.23M
GWAVGreenwave Technology Solutions Inc
US$ 0.649325
(77.90%)
389.87M
JANXJanux Therapeutics Inc
US$ 62.685
(56.01%)
5.24M
JYDJayud Global Logistics Ltd
US$ 1.0411
(55.36%)
9.16M
REVBRevelation Biosciences Inc
US$ 0.5315
(-44.05%)
3.79M
STSSSharps Technology Inc
US$ 2.13
(-36.49%)
361.44k
OMEXOdyssey Marine Exploration Inc
US$ 0.4912
(-34.08%)
3.47M
GELSGelteq Ltd
US$ 2.703
(-29.25%)
224.91k
CYCNCyclerion Therapeutics Inc
US$ 1.67
(-28.63%)
259.85k
GWAVGreenwave Technology Solutions Inc
US$ 0.649325
(77.90%)
389.93M
SMCISuper Micro Computer Inc
US$ 41.2199
(-1.86%)
167.58M
CTNTCheetah Net Supply Chain Service Inc
US$ 5.53
(195.72%)
108.6M
CHRSCoherus BioSciences Inc
US$ 1.9299
(40.87%)
101.99M
NVDANVIDIA Corporation
US$ 139.30
(0.48%)
99.05M

VTVT Discussion

게시물 보기
Awl416 Awl416 9 월 전
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
👍️0
dennisv dennisv 10 월 전
Cowboys2275: You Are Really A Special Cowboy!
https://stocktwits.com/cowboys2275/message/558967191
👍️0
dennisv dennisv 10 월 전
There will be More interest in VTVT!
👍️0
dennisv dennisv 10 월 전
https://zolmax.com/investing/vtv-therapeutics-inc-nasdaqvtvt-sees-large-increase-in-short-interest/9990102.html
👍️0
dennisv dennisv 10 월 전
American Bulls: Buy Signal!
https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=VTVT
👍️0
Monksdream Monksdream 1 년 전
VTVT new 52 week low
👍️0
AJ Freely AJ Freely 1 년 전
$VTVT- 👆Up 16% Pre-Market/Current Price $0.78
👉Cantex Pharmaceuticals Publishes Article in npj Breast Cancer Highlighting Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer
👉Originally developed for Alzheimer's disease by vTv
👍️0
81vette 81vette 2 년 전
2 week long runs in past on news and this is awesome news
👍️0
81vette 81vette 2 년 전
Zero borrow and not optionable,low float target $4,insider trans up 145%
👍️0
81vette 81vette 2 년 전
Zero borrow and not optionable,low float target $4,insider trans up 145%
👍️0
TheFinalCD TheFinalCD 2 년 전
https://finviz.com/quote.ashx?t=VTVT&ty=c&ta=1&p=d
👍️0
N-13 N-13 2 년 전
I guess I spoke too soon.
👍️0
N-13 N-13 2 년 전
Wow, we closed over 70 cents!
👍️0
Investor2014 Investor2014 2 년 전
Because the company keeps spending and raising money without achieving anything.
👍️0
N-13 N-13 2 년 전
Why, so difficult to get over 70 cents?
👍️0
N-13 N-13 3 년 전
What's with the knuckleheads that are trading pre and post market?
👍️0
surf1944 surf1944 3 년 전
https://stockcharts.com/h-sc/ui?s=VTVT&p=D&yr=0&mn=6&dy=0&id=p38090673899

Filled open gap .62 this morning!
👍️0
Golden Cross Golden Cross 3 년 전
$VTVT Huge Vol Alert
👍️0
cjstocksup cjstocksup 3 년 전
@bc9114 The $12.5m ( 5,193,187 shares) in shares distribution to G42 Healthcare were dilutive shares resulting in a increase in total outstanding shares from 90,036,637 to 95,229,824. The float will remain at 30,346,158 because G42 Healthcare will become an affiliate in the next 30 days.

“Lock-Up Period” means the period from the date of this Agreement until December 31, 2024 (or, if earlier, the date of receipt of FDA Approval). I love this Lock-Up Period : ) which is located on page 5.

These particular shares are classified as Unregistered Securities that orginated from the LPC Agreement which had $35.9 remaining available as of March 31st, 2022 & as a result of the G42 Healthcare Partnership the remaining availability under the LPC Agreement is now at $23.4m.

Common Stock Purchase Agreement: (Unregistered Securities)
sec.gov/Archives/edgar/data...

In the next 30 days Vtv's board will increase to 6 & will add
Dr. Fahed Al Marzooqi the COO of G42 Healthcare.
👍️0
cjstocksup cjstocksup 3 년 전
Read today's news it already happened at $2.41 per share.
👍️0
Pt3 Pt3 3 년 전
What a good talk ....when is offering
👍️0
cjstocksup cjstocksup 3 년 전
We churned over the float but those who bought premarket up to $1.18 panic sold on the red open and the rest of the day others panic sold red down. Bottom line the 25-million-dollar investment is huge. We should be up a couple dollars. I am patient. We have more news on the way.
VTVT: This could run-up nicely today, behind substantive news of late and a $5.00 price prediction.
👍️0
Pt3 Pt3 3 년 전
What going on here bulls ....just bought 5000 shares need info
👍️0
crudeoil24 crudeoil24 3 년 전
Yes, I read that filing earlier!
👍️0
cjstocksup cjstocksup 3 년 전
New SEC Filing: 8-K Material Agrmt - vTv Therapeutics Inc. (0001641489) May 31


Item 1.01Entry into a Material Definitive Agreement Common Stock Purchase Agreement On May 31, 2022, vTv Therapeutics Inc. (the "Company") and G42 Investments AI Holding RSC Ltd, a private limited company ("G42 Investments"), entered into a common stock purchase agreement (the "Purchase Agreement"), pursuant to which the Company agreed to sell to G42 Investments 10,386,274 shares of the Company's Class A common stock, par value $0.01 per share (the "Common Stock" and such shares, the "Closing Shares") at a price per share of approximately $2.41, for an aggregate purchase price of $25,000,000, which was paid (i) $12,500,000 in cash at the closing of the transaction and (ii) $12,500,000 in the (...)

marketnewswire.live/index.p...
👍️0
Awl416 Awl416 3 년 전
News
👍️0
crudeoil24 crudeoil24 3 년 전
vTv Therapeutics Announces Entry Into Agreements That Include $25M Investment By G42 Investments AI Holding RSC
6:56 am ET June 1, 2022 (Benzinga) Print
vTv Therapeutics Inc. (NASDAQ:VTVT) today announced entry into agreements that include a $25 million investment by G42 Investments AI Holding RSC Ltd ("G42 Investments"). Under the terms of the agreements, G42 Investments acquired 10,386,274 shares of Class A Common Stock of vTv at an issue price of $2.407 per share, with $12.5 million paid in cash at closing, and the remaining amount of $12.5 million payable on May 31, 2023. The agreements also provide for the potential issuance of $30 million in additional shares of Class A Common Stock to G42 Investments (or cash in lieu of such issuance at the option of G42 Investments) if the United States Food and Drug Administration (the "FDA") approves the marketing and sale of a pharmaceutical product containing TTP399, a liver selective glucokinase activator, as the active ingredient for treatment of type 1 diabetes in the United States. The agreements set forth the terms under which vTv and an affiliate of G42 plan to collaborate on clinical trials for pharmaceutical products that contain TTP399, including G42's affiliate funding a portion of the Phase 3 clinical trials for TTP399, and vTv granting G42's affiliate an exclusive license to develop and commercialize pharmaceutical products containing TTP399 in certain territories outside of the United States and the European Union.

"We have focused substantial energy and resources on TTP399 since obtaining Breakthrough Therapy designation from the FDA in April 2021 and are thrilled to welcome a partner to work with us to accelerate the development and potential approval and commercialization of this treatment. G42 Healthcare brings a unique combination of strong commitment to the development of new impactful drugs and treatments, as demonstrated by their success and their leadership on COVID-19 testing and other product and service offerings in the healthcare spectrum, and substantial resources, making them an ideal partner for this program. This investment into vTv will fund a substantial portion of our Phase 3 clinical trials for TTP399 in the United States and the collaboration with G42 will fund certain of the Phase 3 clinical trials that will be conducted in other territories. We are excited to partner with the G42 Healthcare team as we launch our Phase 3 clinical trials and work together towards approval and commercialization of this treatment for type 1 diabetes," said Rich Nelson, Interim Chief Executive Officer of vTv.

Dr. Fahed Al Marzooqi, the Chief Operating Officer of G42 Healthcare, noted that "We have a deep commitment to collaborating with international organizations to share our knowledge and expertise in the consumer and clinical health spectrum and we look forward to working together with vTv to further develop and commercialize this important treatment. As we move ahead, we will continue to join forces with the world's best to innovate and invest in science and create the next wave of medicines to future-proof the health of nations."

A more detailed description of the agreements is set forth in vTv's Current Report on Form 8-K filed with the SEC. The Stock Purchase Agreement is attached to the Current Report on Form 8-K and the Collaboration and License Agreement will be filed with vTv's Quarterly Report on Form 10-Q for the second quarter.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor will there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
👍️0
Investor2014 Investor2014 3 년 전
Or drop big
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 3 년 전
$VTVT
https://twitter.com/quabbinr/status/1495541185615695880?s=21
👍️0
Just-Keep-Trying Just-Keep-Trying 3 년 전
VTVT: This could run-up nicely today, behind substantive news of late and a $5.00 price prediction.
👍️0
Tom turtles Tom turtles 3 년 전
Really not till the start of 2022....but you never know when they'll drop a biggie
👍️0
murocman murocman 3 년 전
I am surprised this has not gotten more traction and visibility after releasing good trial data.

The Type 1 diabetes market is huge.

Any catalysts in the near term to help out?

Murocman
👍️0
Tom turtles Tom turtles 3 년 전
Too cheap to ignore here !
👍️0
Tom turtles Tom turtles 3 년 전
DWAC.....craziness
👍️0
murocman murocman 3 년 전
Likely because they are woefully behind on their financial filings.

Murocman
👍️0
Tom turtles Tom turtles 3 년 전
Well look at ADMP......they get FDA approval and the stock sells off......ya never know. GL with your trades...
👍️0
Investor2014 Investor2014 3 년 전
P2 trials planned to initiate in 2022. I can’t see those increasing $VTVT as just adding more cost and likely more dilution.

The price of $VTVT going up is linked to the success of those trials.

I might invest at some point before readout if I think the risk/reward looks attractive. Need to see P2 trial protocols first.
👍️0
Tom turtles Tom turtles 3 년 전
Just need it to get past $3 over the next year. Think that's very doable. ITRM and ADMP couple others I'm watching.
👍️0
Tom turtles Tom turtles 3 년 전
Most of his shares were bought above $4. He recently bought 635,000 @ $1.60. I'm closing in on 100,000 shares. Hope I didn't make a mistake here.... Their trials haven't been very successful lately , and recently raised the O/S to 200M shares, which is still very low for a buck stock. ~ You have any other pharm plays that are ripe ? TIA.....
👍️0
Investor2014 Investor2014 3 년 전
Perelman has years ago signed an agreement with vTv funding them on demand by buying the shares they issue.

Insider buying on that basis doesn’t tell you very much other than perhaps Perelman may be a sucker holding a big bag.
👍️0
Tom turtles Tom turtles 3 년 전
It seems he owns about 80% of the company. Not sure how many shares he owns....couldn't find that number on insider trades...
👍️0
Tom turtles Tom turtles 3 년 전
You like this thing Invest2014 ? Right now looks bad.....but 2022 is gonna be huge. Why not accum now...and put in a drawer for a year. No doubt this will bust $5 next year. Been picking up all these $1.40s..New CEO.....inside buying ....lots of things going on here. Huge pipeline...Not just one and done drug. Picking up this and SYN for a long hold.
👍️0
Investor2014 Investor2014 3 년 전
It seems you can have most of the $VTVT that Perelman doesn’t own.
👍️0
Tom turtles Tom turtles 3 년 전
Almost filled up.
👍️0
Tom turtles Tom turtles 3 년 전
Bye buy bye buy
👍️0
Tom turtles Tom turtles 3 년 전
What a turd
👍️0
Tom turtles Tom turtles 3 년 전
I'll be able to buy that new Range Rover I've been looking at.....with cash !
👍️0
Tom turtles Tom turtles 3 년 전
Lol.....hi 1plus1....yes....this is shit right now.....That's why I'm accumulating this for a year from now. Insiders buying in this range...and not just teaser purchases....big buys. This one I'm putting in my closet for next year. Almost have 100,000 shares. Now RNVA you have to watch everyday.....never know when shameless will pull the plug....GL man
👍️0
1plus1 1plus1 3 년 전
This thing is taking the shitzzzz Rnva is a way better buy
👍️0
Tom turtles Tom turtles 3 년 전
Thanks for all the cheapies fellas.....now wait time. Back to $4 sometime this spring. All I have is time !
👍️0